AusCann Group Holdings Ltd

AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AC8.AX stands at 17.62M. In comparison, CAU.AX has a market cap of 300.53M. Regarding current trading prices, AC8.AX is priced at $0.04, while CAU.AX trades at $0.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AC8.AX currently has a P/E ratio of -0.67, whereas CAU.AX's P/E ratio is -16.88. In terms of profitability, AC8.AX's ROE is -0.61%, compared to CAU.AX's ROE of +0.34%. Regarding short-term risk, AC8.AX is less volatile compared to CAU.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AC8.AX.

AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AC8.AX stands at 17.62M. In comparison, AFP.AX has a market cap of 256.92M. Regarding current trading prices, AC8.AX is priced at $0.04, while AFP.AX trades at $2.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AC8.AX currently has a P/E ratio of -0.67, whereas AFP.AX's P/E ratio is 24.50. In terms of profitability, AC8.AX's ROE is -0.61%, compared to AFP.AX's ROE of +0.14%. Regarding short-term risk, AC8.AX is more volatile compared to AFP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.

AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AC8.AX stands at 17.62M. In comparison, PBP.AX has a market cap of 242.34M. Regarding current trading prices, AC8.AX is priced at $0.04, while PBP.AX trades at $2.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AC8.AX currently has a P/E ratio of -0.67, whereas PBP.AX's P/E ratio is 29.80. In terms of profitability, AC8.AX's ROE is -0.61%, compared to PBP.AX's ROE of +0.13%. Regarding short-term risk, AC8.AX is more volatile compared to PBP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.

AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AC8.AX stands at 17.62M. In comparison, LV1.AX has a market cap of 144.06M. Regarding current trading prices, AC8.AX is priced at $0.04, while LV1.AX trades at $0.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AC8.AX currently has a P/E ratio of -0.67, whereas LV1.AX's P/E ratio is 3.05. In terms of profitability, AC8.AX's ROE is -0.61%, compared to LV1.AX's ROE of -4.96%. Regarding short-term risk, AC8.AX is more volatile compared to LV1.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.

AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AC8.AX stands at 17.62M. In comparison, VLS.AX has a market cap of 102.85M. Regarding current trading prices, AC8.AX is priced at $0.04, while VLS.AX trades at $1.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AC8.AX currently has a P/E ratio of -0.67, whereas VLS.AX's P/E ratio is 11.78. In terms of profitability, AC8.AX's ROE is -0.61%, compared to VLS.AX's ROE of +0.17%. Regarding short-term risk, AC8.AX is less volatile compared to VLS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AC8.AX.

AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AC8.AX stands at 17.62M. In comparison, MVP.AX has a market cap of 72.10M. Regarding current trading prices, AC8.AX is priced at $0.04, while MVP.AX trades at $0.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AC8.AX currently has a P/E ratio of -0.67, whereas MVP.AX's P/E ratio is -1.88. In terms of profitability, AC8.AX's ROE is -0.61%, compared to MVP.AX's ROE of -0.59%. Regarding short-term risk, AC8.AX is more volatile compared to MVP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.

AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AC8.AX stands at 17.62M. In comparison, IHL.AX has a market cap of 65.07M. Regarding current trading prices, AC8.AX is priced at $0.04, while IHL.AX trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AC8.AX currently has a P/E ratio of -0.67, whereas IHL.AX's P/E ratio is -0.03. In terms of profitability, AC8.AX's ROE is -0.61%, compared to IHL.AX's ROE of -0.07%. Regarding short-term risk, AC8.AX is less volatile compared to IHL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AC8.AX.

AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AC8.AX stands at 17.62M. In comparison, ANP.AX has a market cap of 52.29M. Regarding current trading prices, AC8.AX is priced at $0.04, while ANP.AX trades at $0.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AC8.AX currently has a P/E ratio of -0.67, whereas ANP.AX's P/E ratio is -2.90. In terms of profitability, AC8.AX's ROE is -0.61%, compared to ANP.AX's ROE of -0.73%. Regarding short-term risk, AC8.AX is less volatile compared to ANP.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AC8.AX.

AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AC8.AX stands at 17.62M. In comparison, VIT.AX has a market cap of 47.68M. Regarding current trading prices, AC8.AX is priced at $0.04, while VIT.AX trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AC8.AX currently has a P/E ratio of -0.67, whereas VIT.AX's P/E ratio is 7.20. In terms of profitability, AC8.AX's ROE is -0.61%, compared to VIT.AX's ROE of +0.05%. Regarding short-term risk, AC8.AX is more volatile compared to VIT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.

AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AC8.AX stands at 17.62M. In comparison, IDT.AX has a market cap of 44.34M. Regarding current trading prices, AC8.AX is priced at $0.04, while IDT.AX trades at $0.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AC8.AX currently has a P/E ratio of -0.67, whereas IDT.AX's P/E ratio is -10.50. In terms of profitability, AC8.AX's ROE is -0.61%, compared to IDT.AX's ROE of -0.19%. Regarding short-term risk, AC8.AX is more volatile compared to IDT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.

AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AC8.AX stands at 17.62M. In comparison, LGP.AX has a market cap of 34.96M. Regarding current trading prices, AC8.AX is priced at $0.04, while LGP.AX trades at $0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AC8.AX currently has a P/E ratio of -0.67, whereas LGP.AX's P/E ratio is -3.83. In terms of profitability, AC8.AX's ROE is -0.61%, compared to LGP.AX's ROE of -0.12%. Regarding short-term risk, AC8.AX is more volatile compared to LGP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.

AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AC8.AX stands at 17.62M. In comparison, NXS.AX has a market cap of 28.92M. Regarding current trading prices, AC8.AX is priced at $0.04, while NXS.AX trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AC8.AX currently has a P/E ratio of -0.67, whereas NXS.AX's P/E ratio is -1.65. In terms of profitability, AC8.AX's ROE is -0.61%, compared to NXS.AX's ROE of -2.01%. Regarding short-term risk, AC8.AX is more volatile compared to NXS.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.

AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AC8.AX stands at 17.62M. In comparison, CPH.AX has a market cap of 23.11M. Regarding current trading prices, AC8.AX is priced at $0.04, while CPH.AX trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AC8.AX currently has a P/E ratio of -0.67, whereas CPH.AX's P/E ratio is -0.45. In terms of profitability, AC8.AX's ROE is -0.61%, compared to CPH.AX's ROE of -1.31%. Regarding short-term risk, AC8.AX is more volatile compared to CPH.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.

AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AC8.AX stands at 17.62M. In comparison, PXS.AX has a market cap of 20.23M. Regarding current trading prices, AC8.AX is priced at $0.04, while PXS.AX trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AC8.AX currently has a P/E ratio of -0.67, whereas PXS.AX's P/E ratio is -1.40. In terms of profitability, AC8.AX's ROE is -0.61%, compared to PXS.AX's ROE of -1.43%. Regarding short-term risk, AC8.AX is more volatile compared to PXS.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.

AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AC8.AX stands at 17.62M. In comparison, AGH.AX has a market cap of 18.92M. Regarding current trading prices, AC8.AX is priced at $0.04, while AGH.AX trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AC8.AX currently has a P/E ratio of -0.67, whereas AGH.AX's P/E ratio is -0.57. In terms of profitability, AC8.AX's ROE is -0.61%, compared to AGH.AX's ROE of -51.14%. Regarding short-term risk, AC8.AX is more volatile compared to AGH.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.

AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AC8.AX stands at 17.62M. In comparison, MXC.AX has a market cap of 18.42M. Regarding current trading prices, AC8.AX is priced at $0.04, while MXC.AX trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AC8.AX currently has a P/E ratio of -0.67, whereas MXC.AX's P/E ratio is -0.13. In terms of profitability, AC8.AX's ROE is -0.61%, compared to MXC.AX's ROE of +5.63%. Regarding short-term risk, AC8.AX is less volatile compared to MXC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AC8.AX.

AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AC8.AX stands at 17.62M. In comparison, ECS.AX has a market cap of 15.55M. Regarding current trading prices, AC8.AX is priced at $0.04, while ECS.AX trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AC8.AX currently has a P/E ratio of -0.67, whereas ECS.AX's P/E ratio is N/A. In terms of profitability, AC8.AX's ROE is -0.61%, compared to ECS.AX's ROE of -0.05%. Regarding short-term risk, AC8.AX is more volatile compared to ECS.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.

AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AC8.AX stands at 17.62M. In comparison, PER.AX has a market cap of 10.87M. Regarding current trading prices, AC8.AX is priced at $0.04, while PER.AX trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AC8.AX currently has a P/E ratio of -0.67, whereas PER.AX's P/E ratio is -0.50. In terms of profitability, AC8.AX's ROE is -0.61%, compared to PER.AX's ROE of N/A. Regarding short-term risk, AC8.AX is more volatile compared to PER.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.

AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AC8.AX stands at 17.62M. In comparison, HGV.AX has a market cap of 10.09M. Regarding current trading prices, AC8.AX is priced at $0.04, while HGV.AX trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AC8.AX currently has a P/E ratio of -0.67, whereas HGV.AX's P/E ratio is -2.40. In terms of profitability, AC8.AX's ROE is -0.61%, compared to HGV.AX's ROE of -0.27%. Regarding short-term risk, AC8.AX is more volatile compared to HGV.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.

AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AC8.AX stands at 17.62M. In comparison, CAN.AX has a market cap of 9.77M. Regarding current trading prices, AC8.AX is priced at $0.04, while CAN.AX trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AC8.AX currently has a P/E ratio of -0.67, whereas CAN.AX's P/E ratio is -0.16. In terms of profitability, AC8.AX's ROE is -0.61%, compared to CAN.AX's ROE of -4.70%. Regarding short-term risk, AC8.AX is less volatile compared to CAN.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AC8.AX.

AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AC8.AX stands at 17.62M. In comparison, EPN.AX has a market cap of 8.29M. Regarding current trading prices, AC8.AX is priced at $0.04, while EPN.AX trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AC8.AX currently has a P/E ratio of -0.67, whereas EPN.AX's P/E ratio is -2.40. In terms of profitability, AC8.AX's ROE is -0.61%, compared to EPN.AX's ROE of -0.13%. Regarding short-term risk, AC8.AX is less volatile compared to EPN.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AC8.AX.

AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AC8.AX stands at 17.62M. In comparison, IVX.AX has a market cap of 7.59M. Regarding current trading prices, AC8.AX is priced at $0.04, while IVX.AX trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AC8.AX currently has a P/E ratio of -0.67, whereas IVX.AX's P/E ratio is -0.89. In terms of profitability, AC8.AX's ROE is -0.61%, compared to IVX.AX's ROE of -0.49%. Regarding short-term risk, AC8.AX is more volatile compared to IVX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.

AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AC8.AX stands at 17.62M. In comparison, EOF.AX has a market cap of 7.33M. Regarding current trading prices, AC8.AX is priced at $0.04, while EOF.AX trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AC8.AX currently has a P/E ratio of -0.67, whereas EOF.AX's P/E ratio is -0.50. In terms of profitability, AC8.AX's ROE is -0.61%, compared to EOF.AX's ROE of -0.51%. Regarding short-term risk, AC8.AX is less volatile compared to EOF.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AC8.AX.

AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AC8.AX stands at 17.62M. In comparison, CGB.AX has a market cap of 5.61M. Regarding current trading prices, AC8.AX is priced at $0.04, while CGB.AX trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AC8.AX currently has a P/E ratio of -0.67, whereas CGB.AX's P/E ratio is -0.70. In terms of profitability, AC8.AX's ROE is -0.61%, compared to CGB.AX's ROE of +0.00%. Regarding short-term risk, AC8.AX is more volatile compared to CGB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.

AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AC8.AX stands at 17.62M. In comparison, BOD.AX has a market cap of 4.26M. Regarding current trading prices, AC8.AX is priced at $0.04, while BOD.AX trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AC8.AX currently has a P/E ratio of -0.67, whereas BOD.AX's P/E ratio is -0.40. In terms of profitability, AC8.AX's ROE is -0.61%, compared to BOD.AX's ROE of +0.66%. Regarding short-term risk, AC8.AX is less volatile compared to BOD.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AC8.AX.

AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AC8.AX stands at 17.62M. In comparison, SCU.AX has a market cap of 3.85M. Regarding current trading prices, AC8.AX is priced at $0.04, while SCU.AX trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AC8.AX currently has a P/E ratio of -0.67, whereas SCU.AX's P/E ratio is N/A. In terms of profitability, AC8.AX's ROE is -0.61%, compared to SCU.AX's ROE of -0.66%. Regarding short-term risk, AC8.AX is less volatile compared to SCU.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AC8.AX.

AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AC8.AX stands at 17.62M. In comparison, EXL.AX has a market cap of 3.75M. Regarding current trading prices, AC8.AX is priced at $0.04, while EXL.AX trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AC8.AX currently has a P/E ratio of -0.67, whereas EXL.AX's P/E ratio is -1.70. In terms of profitability, AC8.AX's ROE is -0.61%, compared to EXL.AX's ROE of -0.20%. Regarding short-term risk, AC8.AX is less volatile compared to EXL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AC8.AX.

AC8.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AC8.AX stands at 17.62M. In comparison, TSN.AX has a market cap of 1.41M. Regarding current trading prices, AC8.AX is priced at $0.04, while TSN.AX trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AC8.AX currently has a P/E ratio of -0.67, whereas TSN.AX's P/E ratio is -0.33. In terms of profitability, AC8.AX's ROE is -0.61%, compared to TSN.AX's ROE of -0.97%. Regarding short-term risk, AC8.AX is more volatile compared to TSN.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AC8.AX.